Article Text

Download PDFPDF

4CPS-106 Safety of adjuvant trastuzumab emtansina for residual invasive HER2-positive early breast cancer
  1. A Martínez Pradeda,
  2. MT Rabuñal Alvarez,
  3. F Busto Fernández,
  4. T Calleja Chucla,
  5. M Mateos Salvador,
  6. E Fernandez Gabriel,
  7. A Luaces Rodriguez,
  8. P Feijoo Vilanova,
  9. S Rotea Salvo,
  10. C Fernández Oliveira,
  11. MI Martin Herranz
  1. Complexo Hospitalario Universitario A Coruña, Pharmacy Service, A Coruna, Spain


Background and importance Trastuzumab-emtansine (T-DM1) is a treatment approved by the European Medicines Agency (EMA) in 2020 as a single agent for the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2-targeted therapy, in which it demostrated a significant improvement in invasive disease-free survival compared with trastuzumab.1

Aim and objectives Aim: to describe our experience with T-DM1 adjuvant for EBC treatment in real-world conditions (RWC). We analysed the T-DM1 safety profile and compared it with a pivotal trial (PT).1

Material and methods Retrospective study in a tertiary hospital. 100% patients with EBC treated with adjuvant T-DM1 between 2019 and 2021.

Demographic data, basal Eastern Cooperative Oncology Group (ECOG), neoadjuvant therapy schedule, T-DM1 cycles received, adverse events (AEs), pegfilgastrim use, intentional dose delays, treatment interruptions and dose reductions were collected.

Results 29 patients received T-DM1. 100% women, average age 52 (range 27–75) years. 2/29 basal ECOG ≥1.

20/29 received neoadjuvant treatment based on doxorubicin (lyposomal or conventional) and cyclophosphamide followed by taxanes (19/20 paclitaxel, 1/20 docetaxel) with trastuzumab and pertuzumab. 24/29 presented toxicities to neoadjuvant treatment (15/29 thrombocytopenia).

T-DM1 starting dose: 3.6 mg/kg/21 days in 28/29 patients. In 1/29, 3 mg/kg due to persistent thrombocytopenia. 10/29 receiving therapy at the time of the study. 8/19 received <14 cycles, 5/8 discontinued due to toxicities.

19/29 experienced ≥1 AE. Grade ≥3 thrombocytopenia was the most common (12/29), followed by increase in liver enzymes (ILE) (6/29), grade ≥2 neuropathy and grade ≥2 asthenia (5/29).

2/29 received pegfilgrastim.

3/29 patients had dose reduction (2/29 one, 1/29 two dose-level reductions). 7/29 experienced dose delays due to toxicities.

Comparison RWC vs PT: any grade AE 65.5% vs 98.8%; grade ≥3 thrombocytopenia 41.4% vs 5.7%; grade ≥2 neuropathy 34.5% vs 1.5%; ILE 20.7% vs 5.6%; discontinuation due to toxicities 17.2% vs 18.0%; dose reductions 10.3% vs 10.4%. Dose delays and reduced initial dose were not considered in the PT.

Conclusion and relevance Safety profile of T-DM1 in RWC is consistent with the PT results. Overall AEs in RCW were lower than in the PT. Grade ≥2 AEs were higher in RWC but not related to increased discontinuations or dose reductions. Our results should be interpreted with caution due to the sample size.

References and/or acknowledgements 1. von Minckwitz G, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019;380(7):617–628.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.